Facts have come to light on the CDC’s handling of COVID-19 treatments in the following post:  https://madisonarealymesupportgroup.com/2020/04/26/cdc-playbook-learning-from-lyme/.

Details revealing more conflicts of interest and why the CDC promotes remdesivir and bad-mouths hydroxychloroquine.  Authorities gave the anti-viral drug an emergency use authorization (EUA) while requiring two months of successful use of hydroxychoroquine in China and South Korea to get a similar EUA.  We keep being told HCQ needs to be in a large double-blind placebo controlled study because it has scary side-effects.  Please know remdesivir also has side effects but is the preference of authorities due to profits.

Nitpicking and blackballing treatments is common with Lyme/MSIDS too.

Here’s what’s been added to the link above:

In the case of COVID-19, severe patients can quickly die, making those studies of little use in the present. Treatments are needed now, not in six months. Doctors and pharmacists go to school to learn about drugs and their interactions. How about authorities just let doctors do their jobs? I don’t see these authorities condemning cancer treatments which kill as many good cells as bad cells.  Why the focus on HCQ?  This recent article explains why.  In essence, the CDC is in bed with Gilead Science as nine of the experts on the NIH COVID-19 Panel recommending treatment options have disclosed financial support from Gilead.

Gilead Science created the anti-viral remdesivir which was unsuccessful for Ebola.  They are now digging it out of the drug graveyard and pushing it for COVID-19 to make up for lost profits. HCQ, even though it’s clinically showing great success, stands in the way of their chosen profitable treatment. Remdesivir is not without side-effects and only showed modest benefits against COVID-19 but this is the CDC’s “golden” treatment, therefore, everything said about it is positive while they bad-mouth HCQ.

So there you have it.  This is what our authorities care about.  Profits.
%d bloggers like this: